Eledon Pharmaceuticals, Inc.
ELDN
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.78% | 3.75% | 27.37% | 117.50% | 18.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.02% | 70.55% | 65.28% | 138.89% | 83.16% |
| Operating Income | 7.02% | -70.55% | -65.28% | -138.89% | -83.16% |
| Income Before Tax | -122.68% | 75.02% | 72.51% | -46.80% | 877.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.68% | 75.02% | 72.51% | -48.23% | 877.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.68% | 75.02% | 72.51% | -48.23% | 877.01% |
| EBIT | 7.02% | -70.55% | -65.28% | -138.89% | -83.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -111.82% | 90.40% | 89.31% | 40.37% | 678.37% |
| Normalized Basic EPS | -115.28% | 86.20% | 89.32% | 36.87% | 547.29% |
| EPS Diluted | 20.04% | 90.40% | 89.31% | 40.37% | 14.52% |
| Normalized Diluted EPS | -116.32% | 86.20% | 89.32% | 36.87% | 518.83% |
| Average Basic Shares Outstanding | 48.42% | 81.02% | 157.18% | 132.53% | 73.68% |
| Average Diluted Shares Outstanding | 38.99% | 81.02% | 157.18% | 132.53% | 85.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |